The combination of lenalidomide (Revlimid) with rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; R2
-CHOP) did not improve progression-free survival (PFS) compared with placebo and R-CHOP as a frontline therapy in patients with activated B-cell (ABC)-type diffuse large B-cell lymphoma (DLBCL), missing the primary endpoint of the phase III ROBUST trial.1
- Celgene Reports First Quarter 2019 Operating and Financial Results. Celgene. Published April 25, 2019. https://bit.ly/2UX0RGZ. Accessed April 25, 2019.
- Nowakowski GS, Chiappella A, Witzig TE, et al. Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST). J Clin Oncol. 2018;36 (suppl 15; abstr 7548). doi: 10.1200/JCO.2018.36.15_suppl.7548.
- Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol. 2015;33(3):251-257. doi: 10.1200/JCO.2014.55.5714.
- Vitolo U, Chiappella A, Franceschetti S, et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol. 2014;15(7):730-737. doi: 10.1016/S1470-2045(14)70191-3.
... to read the full story